Kras and Hras - what is the difference?

被引：9

作者：

Berns, Anton ^{[1
,2
]}

机构：

[1] Netherlands Canc Inst, Div Mol Genet, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands

[2] Netherlands Canc Inst, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands

来源：

NATURE GENETICS | 2008年 / 40卷 / 10期

关键词：

D O I：

10.1038/ng1008-1149

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Kras, Hras or Nras mutations occur at varying frequencies across different tumors in humans for unknown reasons. a new study shows that, in mice, locus-specific regulatory elements determine whether mutations in Hras or Kras will predominate in lung and skin tumors.

引用

收藏

页码：1149 / 1150

页数：3

相关论文

共 13 条

[1]

BOS JL, 1989, CANCER RES, V49, P4682

[2] Ras proteins: Different signals from different locations [J].

Hancock, JF .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (05) :373-384

[3] Farnesyl transferase inhibitors for patients with lung cancer [J].

Johnson, BE ;

Heymach, JV .

CLINICAL CANCER RESEARCH, 2004, 10 (12) :4254S-4257S

[4] Somatic activation of the K-ras oncogene causes early onset lung cancer in mice [J].

Johnson, L ;

Mercer, K ;

Greenbaum, D ;

Bronson, RT ;

Crowley, D ;

Tuveson, DA ;

Jacks, T .

NATURE, 2001, 410 (6832) :1111-1116

[5] INHIBITION OF FARNESYLTRANSFERASE INDUCES REGRESSION OF MAMMARY AND SALIVARY CARCINOMAS IN RAS TRANSGENIC MICE [J].

KOHL, NE ;

OMER, CA ;

CONNER, MW ;

ANTHONY, NJ ;

DAVIDE, JP ;

DESOLMS, SJ ;

GIULIANI, EA ;

GOMEZ, RP ;

GRAHAM, SL ;

HAMILTON, K ;

HANDT, LK ;

HARTMAN, GD ;

KOBLAN, KS ;

KRAL, AM ;

MILLER, PJ ;

MOSSER, SD ;

ONEILL, TJ ;

RANDS, E ;

SCHABER, MD ;

GIBBS, JB ;

OLIFF, A .

NATURE MEDICINE, 1995, 1 (08) :792-797

[6] Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets [J].

Konstantinopoulos, Panagiotis A. ;

Karamouzis, Michalis V. ;

Papavassiliou, Athanasios G. .

NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (07) :540-555

[7] Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development [J].

Mijimolle, N ;

Velasco, J ;

Dubus, P ;

Guerra, C ;

Weinbaum, CA ;

Casey, PJ ;

Campuzano, V ;

Barbacid, M .

CANCER CELL, 2005, 7 (04) :313-324

[8] The pro-apoptotic K-Ras 4A proto-oncoprotein does not affect tumorigenesis in the ApcMin/+ mouse small intestine [J].

Patek, Charles E. ;

Arends, Mark J. ;

Rose, Lorraine ;

Luo, Feijun ;

Walker, Marion ;

Devenney, Paul S. ;

Berry, Rachel L. ;

Lawrence, Nicola J. ;

Ridgway, Rachel A. ;

Sansom, Owen J. ;

Hooper, Martin L. .

BMC GASTROENTEROLOGY, 2008, 8 (1)

[9] Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis [J].

Patek, Charles E. ;

Arends, Mark J. ;

Wallace, William A. H. ;

Luo, Feijun ;

Hagan, Suzanne ;

Brownstein, David G. ;

Rose, Lorraine ;

Devenney, Paul S. ;

Walker, Marion ;

Plowman, Sarah ;

Berry, Rachel L. ;

Kolch, Walter ;

Sansom, Owen J. ;

Harrison, David J. ;

Hooper, Martin L. .

EXPERIMENTAL CELL RESEARCH, 2008, 314 (05) :1105-1114

[10] While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable [J].

Plowman, SJ ;

Williamson, DJ ;

O'Sullivan, MJ ;

Doig, J ;

Ritchie, AM ;

Harrison, DJ ;

Melton, DW ;

Arends, MJ ;

Hooper, ML ;

Patek, CE .

MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (24) :9245-9250